Abstract
Tolperisone, a muscle relaxant used for post-stroke spasticity, has been reported to have a very wide interindividual pharmacokinetic variability. It is metabolized mainly by CYP2D6 and, to a lesser extent, by CYP2C19 and CYP1A2. CYP2D6 is a highly polymorphic enzyme, and CYP2D6*wt/*wt, CYP2D6*wt/*10 and CYP2D6*10/*10 genotypes constitute more than 90% of the CYP2D6 genotypes in the Korean population. Thus, effects of the CYP2D6*10 on tolperisone pharmacokinetics were investigated in this study to elucidate the reasons for the wide interindividual variability. Oral tolperisone 150 mg was given to sixty-four healthy Koreans, and plasma concentrations of tolperisone were measured by liquid chromatography-tandem mass spectrometry (LC–MS/MS). The CYP2D6*10/*10 and CYP2D6*wt/*10 groups had significantly higher Cmax and lower CL/F values than the CYP2D6*wt/*wt group. The AUCinf of CYP2D6*10/*10 and CYP2D6*wt/*10 groups were 5.18-fold and 2.25-fold higher than the CYP2D6*wt/*wt group, respectively. There were considerable variations in the Cmax and AUC values within each genotype group, and the variations were greater as the activity of CYP2D6 decreased. These results suggest that the genetic polymorphism of CYP2D6 significantly affected tolperisone pharmacokinetics and factor(s) other than CYP2D6 may also have significant effects on the pharmacokinetics of tolperisone.
Similar content being viewed by others
References
Bae JW, Kim MJ, Park YS, Myung CS, Jang CG, Lee SY (2007) Considerable interindividual variation in the pharmacokinetics of tolperisone HCl. Int J Clin Pharmacol Ther 45(2):110–113. https://doi.org/10.5414/cpp45110
Bae JW, Oh KY, Yoon SJ, Shin HB, Jung EH, Cho CK, Lim CW, Kang P, Choi CI, Jang CG, Lee SY, Lee YJ (2020) Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide. Arch Pharm Res 43(11):1207–1213. https://doi.org/10.1007/s12272-020-01293-4
Briskin BS, Dibirov MD, Evseev IuN, Novosel’tsev OS (2000) Treatment of chronic arterial insufficiency of legs with midocalm in elderly. Khirurgiia (mosk) 4:52–54
Byeon J, Lee JY, Jeon JS, Lee JE, Kim SH, Choi CI, Lee YJ, Bae JW, Jang CG, Lee SY (2013) Genetic polymorphism of CYP2D6 significantly affects the pharmacokinetics of tolperisone. Clinical Therapeutics 35(8):e58. https://doi.org/10.1016/j.clinthera.2013.07.158
Byeon JY, Kim YH, Lee CM, Kim SH, Chae WK, Jung EH, Choi CI, Jang CG, Lee SY, Bae JW, Lee YJ (2018) CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes. Arch Pharm Res 41(9):921–930. https://doi.org/10.1007/s12272-018-1075-6
Byeon JY, Kim YH, Na HS, Jang JH, Kim SH, Lee YJ, Bae JW, Kim IS, Jang CG, Chung MW, Lee SY (2015) Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites. Arch Pharm Res 38(11):2083–2091. https://doi.org/10.1007/s12272-015-0646-z
Byeon JY, Lee CM, Lee YJ, Kim YH, Kim SH, Jung EH, Chae WK, Lee YJ, Jang CG, Lee SY (2019) Influence of CYP2D6 genetic polymorphism on pharmacokinetics of active moiety of tolterodine. Arch Pharm Res 42(2):182–190. https://doi.org/10.1007/s12272-018-1099-y
Cho CK, Kang P, Park HJ, Ko E, Mu CY, Lee YJ, Choi CI, Kim HS, Jang CG, Bae JW, Lee SY (2022) Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism. Arch Pharm Res 45(5):352–366. https://doi.org/10.1007/s12272-022-01388-0
Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2021a) Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele. Arch Pharm Res 44(11):1037–1049. https://doi.org/10.1007/s12272-021-01357-z
Cho CK, Park HJ, Kang P, Moon S, Lee YJ, Bae JW, Jang CG, Lee SY (2021b) Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes. Arch Pharm Res 44(12):1076–1090. https://doi.org/10.1007/s12272-021-01361-3
Choi CI, Bae JW, Jang CG, Lee SY (2012a) Tamsulosin exposure is significantly increased by the CYP2D6*10/*10 genotype. J Clin Pharmacol 52(12):1934–1938. https://doi.org/10.1177/0091270011432168
Choi CI, Park JI, Lee HI, Lee YJ, Jang CG, Bae JW, Lee SY (2012b) Determination of tolperisone in human plasma by liquid chromatography/tandem mass spectrometry for clinical application. J Chromatogr B Analyt Technol Biomed Life Sci 911:59–63. https://doi.org/10.1016/j.jchromb.2012.10.027
Correia MA (2021) Drug biotransformation. In: Katzung BG, Vanderah TW (eds) Basic & clinical pharmacology, 15th edn. McGraw Hill, New York, pp 57–76
Dalmadi B, Leibinger J, Szeberényi S, Borbás T, Farkas S, Szombathelyi Z, Tihanyi K (2003) Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos 31(5):631–636. https://doi.org/10.1124/dmd.31.5.631
Furuta Y, Yoshikawa A (1976) Reversible adrenergic alpha-receptor blocking action of 2,4’-dimethyl-3-piperidino-propiophenone (tolperisone). Jpn J Pharmacol 26:543–550. https://doi.org/10.1254/jjp.26.543
Johansson I, Lundqvist E, Dahl ML, Ingelman-Sundberg M (1996) PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 6(4):351–355. https://doi.org/10.1097/00008571-199608000-00008
Jung EH, Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Choi CI, Jang CG, Lee SY (2021) Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients. Arch Pharm Res 44(12):1109–1119. https://doi.org/10.1007/s12272-021-01363-1
Jung EH, Lee CM, Byeon JY, Shin HB, Oh KY, Cho CK, Lim CW, Jang CG, Lee SY, Lee YJ (2020a) Relationship between plasma exposure of zolpidem and CYP2D6 genotype in healthy Korean subjects. Arch Pharm Res 43(9):976–981. https://doi.org/10.1007/s12272-020-01250-1
Jung EH, Lee YJ, Kim DH, Kang P, Lim CW, Cho CK, Jang CG, Lee SY, Bae JW (2020b) Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes. Arch Pharm Res 43(12):1356–1363. https://doi.org/10.1007/s12272-020-01300-8
Kim MJ, Byeon JY, Kim YH, Kim SH, Lee CM, Jung EH, Chae WK, Lee YJ, Jang CG, Lee SY, Choi CI (2018a) Effect of the CYP2D6*10 allele on the pharmacokinetics of clomiphene and its active metabolites. Arch Pharm Res 41(3):347–353. https://doi.org/10.1007/s12272-018-1005-7
Kim NT, Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2022) Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects. Arch Pharm Res 45(2):114–121. https://doi.org/10.1007/s12272-021-01366-y
Kim SH, Byeon JY, Kim YH, Lee CM, Lee YJ, Jang CG, Lee SY (2018b) Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes. Sci Rep 8(1):12405. https://doi.org/10.1038/s41598-018-30841-8
Kim YH, Kang P, Cho CK, Jung EH, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2021) Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism. Arch Pharm Res 44(7):713–724. https://doi.org/10.1007/s12272-021-01346-2
Kocsis P, Farkas S, Fodor L, Bielik N, Thán M, Kolok S, Gere A, Csejtei M, Tarnawa I (2005) Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther 315(3):1237–1246. https://doi.org/10.1124/jpet.105.089805
Lee CM, Jung EH, Byeon JY, Kim SH, Jang CG, Lee YJ, Lee SY (2019) Effects of steady-state clarithromycin on the pharmacokinetics of zolpidem in healthy subjects. Arch Pharm Res 42(12):1101–1106. https://doi.org/10.1007/s12272-019-01201-5
Lee CM, Kang P, Cho CK, Park HJ, Lee YJ, Bae JW, Choi CI, Kim HS, Jang CG, Lee SY (2022) Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes. Arch Pharm Res 45(6):433–445. https://doi.org/10.1007/s12272-022-01394-2
Lundqvist E, Johansson I, Ingelman-Sundberg M (1999) Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 226(2):327–338. https://doi.org/10.1016/s0378-1119(98)00567-8
Mendoza R, Wan YJ, Poland RE, Smith M, Zheng Y, Berman N, Lin KM (2001) CYP2D6 polymorphism in a Mexican American population. Clin Pharmacol Ther 70(6):552–560. https://doi.org/10.1067/mcp.2001.120675
Miskolczi P, Vereczkey L, Frenkl R (1987) Gas-liquid chromatographic method for the determination of tolperisone in human plasma: pharmacokinetic and comparative bioavailability studies. J Pharm Biomed Anal 5(7):695–700. https://doi.org/10.1016/0731-7085(87)80082-1
Pawlowska M, Bogiel M, Duda J, Sieradzki E (2015) Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers. Eur J Clin Pharmacol 71(6):699–705. https://doi.org/10.1007/s00228-015-1856-5
Ribi C, Vermeulen C, Hauser C (2003) Anaphylactic reactions to tolperisone (Mydocalm). Swiss Med Wkly 133:369–371
Shin HB, Jung EH, Kang P, Lim CW, Oh KY, Cho CK, Lee YJ, Choi CI, Jang CG, Lee SY, Bae JW (2020) ABCB1 c.2677G>T/c.3435C>T diplotype increases the early-phase oral absorption of losartan. Arch Pharm Res. 43(11):1187–1196. https://doi.org/10.1007/s12272-020-01294-3
Vora A (2010) Tolperisone. J Assoc Physicians India 58:127–128
Whang SS, Cho CK, Jung EH, Kang P, Park HJ, Lee YJ, Choi CI, Bae JW, Kim HS, Jang CG, Lee SY (2022) Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes. Arch Pharm Res 45(8):584–595. https://doi.org/10.1007/s12272-022-01403-4
Acknowledgements
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT, and Future Planning (NRF-2019R1A2C1004582) and the grant from Ministry of Food and Drug Safety.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Cho, C., Byeon, JY., Kang, P. et al. Effects of CYP2D6*10 allele on the pharmacokinetics of tolperisone. Arch. Pharm. Res. 46, 59–64 (2023). https://doi.org/10.1007/s12272-022-01422-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-022-01422-1